
Get exclusive money-saving offers and guides
Straight to your inbox
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Oragenics, Inc is a biotechnology business with stocks listed in the US. Oragenics shares (OGEN) are listed on the NYSE MKT and all prices are listed in US Dollars. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | US$0.36 - US$2.09 |
---|---|
50-day moving average | US$1.0991 |
200-day moving average | US$0.7001 |
Target price | US$3 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | US$-0.511 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Gross profit TTM | US$0 |
---|---|
Return on assets TTM | -92.15% |
Return on equity TTM | -168.22% |
Profit margin | 0% |
Book value | 0.04 |
Market capitalisation | US$113.6 million |
TTM: trailing 12 months
There are currently 3.3 million Oragenics shares held short by investors – that's known as Oragenics's "short interest". This figure is 24.8% down from 4.4 million last month.
There are a few different ways that this level of interest in shorting Oragenics shares can be evaluated.
Oragenics's "short interest ratio" (SIR) is the quantity of Oragenics shares currently shorted divided by the average quantity of Oragenics shares traded daily (recently around 32.8 million). Oragenics's SIR currently stands at 0.1. In other words for every 100,000 Oragenics shares traded daily on the market, roughly 100 shares are currently held short.
However Oragenics's short interest can also be evaluated against the total number of Oragenics shares, or, against the total number of tradable Oragenics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Oragenics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Oragenics shares in existence, roughly 30 shares are currently held short) or 0.0335% of the tradable shares (for every 100,000 tradable Oragenics shares, roughly 34 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Oragenics.
Find out more about how you can short Oragenics stock.
We're not expecting Oragenics to pay a dividend over the next 12 months.
Oragenics's shares were split on a 1:10 basis on 22 January 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Oragenics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Oragenics shares which in turn could have impacted Oragenics's share price.
Over the last 12 months, Oragenics's shares have ranged in value from as little as US$0.36 up to US$2.09. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Oragenics's is 0.262. This would suggest that Oragenics's shares are less volatile than average (for this exchange).
Oragenics, Inc. develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring compound for use in weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against dental caries, or tooth decay. Oragenics, Inc. has collaboration agreements with Precigen, Inc. and its subsidiary, Intrexon Actobiotics NV to develop AG013; and a license agreement with LPThera LLC to develop LPT3-04. It also has a process development and drug substance manufacturing agreement with Avid Bioservices, Inc. for coronavirus vaccine. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
Steps to owning and managing Liberty Financial Group shares.
Steps to owning and managing Cettire shares.
Steps to owning and managing BHP Group shares.
Steps to owning and managing Fisher & Paykel Healthcare Corp Ltd shares.
From ingestibles to body products, we've rounded up the retailers with a range of hemp seed oils in stock.
From Membership Rewards Points to savings on first and business class flights, this charge card is packed with features to help you manage business spending.
From the best sheets for summer to the most luxurious threads, these are the 7 best bed sheets you can get in Australia right now.
Everything we know about the Bumble IPO, plus information on how to buy in.
Steps to owning and managing MicroStrategy shares.
Everything we know about the Superhero IPO, plus information on how to buy in.